{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:59:55Z","timestamp":1740124795247,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Resolve to Save Lives, an initiative of Vital Strategies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41371-021-00600-w","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T12:05:32Z","timestamp":1632398732000},"page":"989-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-3372","authenticated-orcid":false,"given":"Li","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"3rd","given":"Edgar R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3554-0085","authenticated-orcid":false,"given":"Andrew E.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-2921","authenticated-orcid":false,"given":"Eug\u00e8ne","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"600_CR3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jch.14009","volume":"22","author":"A Salam","year":"2020","unstructured":"Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769\u201379.","journal-title":"J Clin Hypertens"},{"key":"600_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1524-6175.2005.04722.x","volume":"8","author":"V Papademetriou","year":"2006","unstructured":"Papademetriou V. Diuretics, hypokalemia, and cardiac arrhythmia: a 20-year controversy. J Clin Hypertens. 2006;8:86\u201392.","journal-title":"J Clin Hypertens"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.129171","volume":"54","author":"DH Ellison","year":"2009","unstructured":"Ellison DH, Loffing J. Thiazide effects and adverse effects: insights from molecular genetics. Hypertension. 2009;54:196\u2013202.","journal-title":"Hypertension"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/HYPERTENSIONAHA.111.180554","volume":"59","author":"MH Alderman","year":"2012","unstructured":"Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59:926\u201333.","journal-title":"Hypertension"},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","volume":"30","author":"MA Raebel","year":"2012","unstructured":"Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30:e156\u2013e166.","journal-title":"Cardiovasc Ther"},{"key":"600_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/cpt.2130","volume":"109","author":"J Maringwa","year":"2021","unstructured":"Maringwa J, Sardu ML, Hang Y, Czerniak R, Vishnubhotla M, Vakilynejad M, et al. Characterizing effects of antidiabetic drugs on heart rate, systolic and diastolic blood pressure. Clin Pharmacol Ther. 2021;109:1583\u201392.","journal-title":"Clin Pharmacol Ther."},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jcph.781","volume":"57","author":"N Plock","year":"2017","unstructured":"Plock N, Bax L, Lee D, DeManno D, Lahu G, Pfister M. Exploratory literature meta-analysis to characterize the relationship between early and longer term body weight loss for antiobesity compounds. J Clin Pharm. 2017;57:52\u201363.","journal-title":"J Clin Pharm"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1038\/psp.2012.23","volume":"2","author":"H Naik","year":"2013","unstructured":"Naik H, Lu J, Cao C, Pfister M, Vakilynejad M, Leifke E. Pharmacometric approaches to guide dose selection of the novel GPR40 agonist TAK-875 in subjects with type 2 diabetes mellitus. CPT Pharmacomet Syst Pharm. 2013;2:e22.","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/clpt.2011.242","volume":"90","author":"JW Mandema","year":"2011","unstructured":"Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharm Ther. 2011;90:766\u20139.","journal-title":"Clin Pharm Ther"},{"doi-asserted-by":"crossref","unstructured":"Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6.","key":"600_CR12","DOI":"10.1161\/JAHA.116.005428"},{"key":"600_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S Oparil","year":"2010","unstructured":"Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252\u201369.","journal-title":"Clin Ther"},{"unstructured":"Daiichi Sankyo Inc. Study of co-administration of olmesartan medoxomil plus amlodipine in patients with mild to severe hypertension. 2005. [Accessed 2020; ClinicalTrials.gov identifier: NCT00185133].","key":"600_CR14"},{"unstructured":"Daiichi Sankyo Inc. Olmesartan as an add-on to amlodipine in hypertension. 2005. [Accessed 2020; ClinicalTrials.gov identifier: NCT00220233].","key":"600_CR15"},{"unstructured":"Daiichi Sankyo Inc. Azor (amlodipine and olmesartan medoxomil) 5\/20, 5\/40, 10\/20, and 10\/40\u2009mg tablets, medical reviews NDA22-100. In: FDA, 2007. [Accessed 2020; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022100_azor_toc.cfm","key":"600_CR16"},{"unstructured":"Novartis. Clinical & Statistical Review NDA 22-314. In: FDA, 2009. Accessed 2020; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022314s000_MedR.pdf.","key":"600_CR17"},{"key":"600_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/sj.jhh.1000718","volume":"12","author":"JR Benz","year":"1998","unstructured":"Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861\u20136.","journal-title":"J Hum Hypertens"},{"unstructured":"Daiichi Sankyo Inc. Safety and efficacy study of a triple combination therapy in subjects with hypertension. 2010. [Accessed 2020; ClinicalTrials.gov identifier: NCT00649389].","key":"600_CR19"},{"key":"600_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/01.HYP.35.5.1025","volume":"35","author":"LV Franse","year":"2000","unstructured":"Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension Elder Program. Hypertension. 2000;35:1025\u201330.","journal-title":"Hypertension"},{"key":"600_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","volume":"277","author":"BM Psaty","year":"1997","unstructured":"Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739\u201345.","journal-title":"JAMA"},{"key":"600_CR22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","volume":"59","author":"MA Peterzan","year":"2012","unstructured":"Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104\u20139.","journal-title":"Hypertension"},{"key":"600_CR23","doi-asserted-by":"publisher","first-page":"e006415","DOI":"10.1161\/CIRCOUTCOMES.119.006415","volume":"13","author":"RV Parikh","year":"2020","unstructured":"Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, et al. Kidney function and potassium monitoring after initiation of renin-angiotensin-aldosterone system blockade therapy and outcomes in 2 north American populations. Circ Cardiovasc Qual Outcomes. 2020;13:e006415.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535\u201342.","journal-title":"Eur Heart J"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00600-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:04:39Z","timestamp":1668125079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1038\/s41371-021-00600-w","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"type":"print","value":"0950-9240"},{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}